Charles Samuel, Wiseman Scott, Wang Xinshuo, Savadelis Molly D, Reinemeyer Craig R, Bouzaidi Cheikhi Imad, Rautenbach Carin, Young Lisa
Elanco Animal Health, Innovation Way, Greenfield, IN, 46140, USA.
Elanco Animal Health, Bartley Way, Hook, RG27 9XA, UK.
Parasit Vectors. 2025 Aug 20;18(1):356. doi: 10.1186/s13071-025-06968-9.
Roundworms such as Toxascaris leonina and Toxocara canis are routinely diagnosed in dogs globally, especially in dogs 6 months of age or younger. Toxocara canis is zoonotic, can cause significant disease in dogs, and is the causative agent of toxocariasis in humans. To protect both animal and human health, it is imperative that Toxocara canis infections are effectively treated and controlled to minimize the risk of transmission. The following studies were performed to demonstrate the effectiveness and safety of a novel, combination chewable tablet (Credelio Quattro) containing the minimum effective dosages of lotilaner (20.0 mg/kg), moxidectin (0.02 mg/kg), praziquantel (5.0 mg/kg), and pyrantel (5.0 mg/kg) for the treatment and control of T. canis and T. leonina infections in dogs.
Six well-controlled studies were performed. Two studies each evaluated Credelio Quattro against immature adult T. canis, adult T. canis, and adult T. leonina infections. Post-treatment efficacy was calculated from necropsy worm counts, and fecal egg count reduction was determined 10 days post-treatment in studies evaluating experimentally induced or naturally acquired adult infections.
Credelio Quattro was safe and ≥ 97.9% effective against immature adult stages and ≥ 97.0% effective against adult stages of induced and natural T. canis infections in dogs. After treatment with Credelio Quattro, fecal egg counts were reduced by ≥ 98.8% in T. canis-infected dogs. In both experimentally induced and naturally acquired adult T. leonina infections in dogs, Credelio Quattro was safe and 100% effective in eliminating adult worms and provided 100% reduction in fecal egg counts post-treatment. The most common adverse events reported included digestive tract disorders such as diarrhea, mucus and/or blood in feces, vomiting, and expelled ascarid worms, which occurred in both control- and treated-groups.
These laboratory studies confirm the effectiveness and safety of a single dose of Credelio Quattro, administered at the minimum dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5 mg/kg praziquantel, and 5 mg/kg pyrantel, for the treatment and control of immature adult and adult T. canis and adult T. leonina in dogs.
全球范围内，犬弓首蛔虫和狮弓蛔虫等蛔虫在犬类中常被诊断出来，尤其是6月龄及以下的幼犬。犬弓首蛔虫是人畜共患病原体，可在犬类中引发严重疾病，也是人类弓首蛔虫病的病原体。为保护动物和人类健康，必须有效治疗和控制犬弓首蛔虫感染，以降低传播风险。进行了以下研究，以证明一种新型复方咀嚼片（Credelio Quattro）的有效性和安全性，该咀嚼片含有最低有效剂量的氯虫苯甲酰胺（20.0毫克/千克）、莫西菌素（0.02毫克/千克）、吡喹酮（5.0毫克/千克）和噻嘧啶（5.0毫克/千克），用于治疗和控制犬类的犬弓首蛔虫和狮弓蛔虫感染。
进行了六项严格对照的研究。每项研究中有两项分别评估了Credelio Quattro对未成熟成虫期犬弓首蛔虫、成虫期犬弓首蛔虫和成虫期狮弓蛔虫感染的效果。治疗后的疗效通过尸检时的蠕虫计数计算得出，在评估实验性诱导或自然获得的成虫感染的研究中，在治疗后10天测定粪便虫卵计数减少情况。
Credelio Quattro安全有效，对未成熟成虫期犬弓首蛔虫的有效性≥97.9%，对诱导和自然感染的犬弓首蛔虫成虫期的有效性≥97.0%。用Credelio Quattro治疗后，感染犬弓首蛔虫的犬类粪便虫卵计数减少≥98.8%。在实验性诱导和自然获得的犬狮弓蛔虫成虫感染中，Credelio Quattro安全有效，能100%消除成虫，并使治疗后粪便虫卵计数减少100%。报告的最常见不良事件包括消化道疾病，如腹泻、粪便中有黏液和/或血液、呕吐以及排出蛔虫，这些在对照组和治疗组中均有发生。
这些实验室研究证实了单剂量Credelio Quattro以20毫克/千克氯虫苯甲酰胺、0.
